logo
NXTC_Logo
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update and reported third quarter 2022 financial results

By NextCure
Published - Nov 03, 2022, 04:18 PM ET
Last Updated - Mar 18, 2024, 02:07 PM EDT
  • Discontinuing development of our NC318 program
  • Advancing clinical pipeline: NC410 combination, NC525, and NC762
  • Extending runway into mid-2025 (an additional 15 months)
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024